BRIEF published on 09/24/2024 at 23:05, 1 year 10 months ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 1 year 10 months ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 1 year 10 months ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 1 year 10 months ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 1 year 10 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 1 year 10 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 1 year 11 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 1 year 11 months ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 1 year 11 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 1 year 11 months ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
Published on 08/18/2026 at 02:20, 5 hours 8 minutes ago Numerous High-Grade Assays Extend Tolmer Silver Discovery
Published on 08/17/2026 at 22:30, 8 hours 58 minutes ago Matador Technologies Amends Convertible Note Facility to Expand At the Market Capacity and Commit a Fixed Share of Proceeds to Bitcoin
Published on 08/17/2026 at 21:00, 10 hours 28 minutes ago Taranis Announces New Critical Minerals By-Product Findings at the Thor and Ajax Mines
Published on 08/17/2026 at 15:00, 16 hours 28 minutes ago Norsemont Appoints Ariel Tepperman to Its Board
Published on 08/18/2026 at 06:45, 43 minutes ago The Medartis Group accelerates organic sales growth in H1 to 17.0% and achieves a core EBITDA margin of 18.0%
Published on 08/18/2026 at 06:45, 43 minutes ago HUBER+SUHNER sees continued positive order momentum and invests in future growth
Published on 08/18/2026 at 06:00, 1 hour 28 minutes ago SKAN achieves double-digit growth in order intake and net sales in the first half of the year and confirms guidance for the full year
Published on 08/17/2026 at 19:45, 11 hours 43 minutes ago Aéroports de Paris S.A - July 2026 traffic figures
Published on 08/17/2026 at 19:45, 11 hours 43 minutes ago Aéroports de Paris S.A - Trafic du mois de juillet 2026
Published on 08/17/2026 at 17:45, 13 hours 43 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/17/2026 at 17:40, 13 hours 48 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 10 au 14 août 2026 dans le cadre du programme de rachat d’actions.
